Action CMMB CHEMOMAB THERAPEUTICS LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Chemomab Therapeutics Ltd.

Actions

CMMB

US16385C1045

Temps Différé Nasdaq
Autres places de cotation
 17:16:38 17/07/2024 		Varia. 5j. Varia. 1 janv.
1,165 USD +4,02 % Graphique intraday de Chemomab Therapeutics Ltd. +3,10 % +128,43 %
18/06 Chemomab Therapeutics Ltd. annonce de nouvelles publications renforçant le potentiel clinique de son anticorps neutralisant la protéine CCL24, le CM-101, dans la cholangite sclérosante primaire. CI
06/05 CHEMOMAB THERAPEUTICS LTD. : Oppenheimer réajuste son opinion à la hausse ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
GL
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
GL
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
AQ
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
AQ
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
GL
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GL
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GL
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
AQ
Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company’s annual general meeting of the shareholders (the “Meeting”) to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting - Form 6-K
PU
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
GL
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
GL
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
AQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
GL
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
GL
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
AQ
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
GL
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
AQ
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
AQ
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
PR
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CMMB
  4. Actualités Chemomab Therapeutics Ltd.
  5. Communiqués